{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:48:33Z","timestamp":1787579313030,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005923","name":"International Association for the Study of Lung Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.lungcan.2020.09.022","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T02:01:16Z","timestamp":1601517676000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort"],"prefix":"10.1016","volume":"150","author":[{"given":"Puey Ling","family":"Chia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prudence","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashi","family":"Asadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibhusal","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Murone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Walkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.lungcan.2020.09.022_bib0005","first-page":"4010","article-title":"Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth","volume":"60","author":"Ryan","year":"2000","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2020.09.022_bib0010","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/08977199209046408","article-title":"Platelet-derived growth factor is angiogenic in vivo","volume":"7","author":"Risau","year":"1992","journal-title":"Growth Factors."},{"issue":"4787","key":"10.1016\/j.lungcan.2020.09.022_bib0015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1126\/science.2432664","article-title":"Angiogenic factors","volume":"235","author":"Folkman","year":"1987","journal-title":"Science."},{"issue":"1","key":"10.1016\/j.lungcan.2020.09.022_bib0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat Rev Cancer."},{"issue":"3","key":"10.1016\/j.lungcan.2020.09.022_bib0025","first-page":"153","article-title":"Role of tumour-associated macrophages in cancer-related inflammation","volume":"32","author":"Sica","year":"2010","journal-title":"Exp Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.09.022_bib0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2174\/138161209787315783","article-title":"Regulation of angiogenesis by macrophages, dendritic cells, and circulating myelomonocytic cells","volume":"15","author":"David Dong","year":"2009","journal-title":"Curr Pharm Des."},{"issue":"9-10","key":"10.1016\/j.lungcan.2020.09.022_bib0035","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.imbio.2009.06.014","article-title":"Cellular and molecular pathways linking inflammation and cancer","volume":"214","author":"Porta","year":"2009","journal-title":"Immunobiology."},{"issue":"5","key":"10.1016\/j.lungcan.2020.09.022_bib0040","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1378\/chest.128.5.3382","article-title":"Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma","volume":"128","author":"Demirag","year":"2005","journal-title":"Chest."},{"issue":"1","key":"10.1016\/j.lungcan.2020.09.022_bib0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br J Cancer."},{"issue":"5","key":"10.1016\/j.lungcan.2020.09.022_bib0050","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1378\/chest.124.5.1916","article-title":"Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma","volume":"124","author":"Edwards","year":"2003","journal-title":"Chest."},{"key":"10.1016\/j.lungcan.2020.09.022_bib0055","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","author":"Zalcman","year":"2015","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.lungcan.2020.09.022_bib0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat Rev Drug Discov."},{"issue":"3","key":"10.1016\/j.lungcan.2020.09.022_bib0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The Fibroblast Growth Factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip Rev Dev Biol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.09.022_bib0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer."},{"issue":"10","key":"10.1016\/j.lungcan.2020.09.022_bib0075","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1016\/j.jtho.2019.08.691","article-title":"MA23.01 Phase II Trial of an Oral FGFR Inhibitor AZD4547 as Second or Third Line Therapy in Malignant Pleural Mesothelioma: Final Results of FRAME Study","volume":"14","author":"Lam","year":"2019","journal-title":"Journal of Thoracic Oncology."},{"issue":"1","key":"10.1016\/j.lungcan.2020.09.022_bib0080","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1078-0432.CCR-17-1172","article-title":"Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition","volume":"24","author":"Quispel-Janssen","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"7","key":"10.1016\/j.lungcan.2020.09.022_bib0085","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","article-title":"Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy","volume":"190","author":"Schelch","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"issue":"4","key":"10.1016\/j.lungcan.2020.09.022_bib0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cytogfr.2004.03.007","article-title":"The PDGF family: four gene products form five dimeric isoforms","volume":"15","author":"Fredriksson","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"issue":"5","key":"10.1016\/j.lungcan.2020.09.022_bib0095","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/35010579","article-title":"PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor","volume":"2","author":"Li","year":"2000","journal-title":"Nat Cell Biol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.09.022_bib0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1359-6101(02)00090-4","article-title":"Novel PDGF family members: PDGF-C and PDGF-D","volume":"14","author":"Li","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"issue":"12","key":"10.1016\/j.lungcan.2020.09.022_bib0105","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1096\/fj.02-0319com","article-title":"Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors","volume":"16","author":"Cao","year":"2002","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.lungcan.2020.09.022_bib0110","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nm.4494","article-title":"Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling","volume":"24","author":"Roswall","year":"2018","journal-title":"Nat Med."},{"issue":"12","key":"10.1016\/j.lungcan.2020.09.022_bib0115","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/14737140.2016.1244008","article-title":"Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma","volume":"16","author":"Chia","year":"2016","journal-title":"Expert Rev Anticancer Ther."},{"issue":"31","key":"10.1016\/j.lungcan.2020.09.022_bib0120","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib Plus Pemetrexed\/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J Clin Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2020.09.022_bib0125","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med."},{"issue":"11","key":"10.1016\/j.lungcan.2020.09.022_bib0130","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2020.09.022_bib0135","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J Thorac Oncol."},{"issue":"15","key":"10.1016\/j.lungcan.2020.09.022_bib0140","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1158\/1078-0432.CCR-17-1507","article-title":"Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo","volume":"24","author":"Laszlo","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2020.09.022_bib0145","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/S1556-0864(18)30486-6","article-title":"213O Nintedanib + pemetrexed\/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study","volume":"13","author":"Pavlakis","year":"2018","journal-title":"Journal of Thoracic Oncology."},{"issue":"3","key":"10.1016\/j.lungcan.2020.09.022_bib0150","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer."},{"issue":"7","key":"10.1016\/j.lungcan.2020.09.022_bib0155","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.pathol.2016.08.003","article-title":"Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma","volume":"48","author":"Thapa","year":"2016","journal-title":"Pathology."},{"key":"10.1016\/j.lungcan.2020.09.022_bib0160","first-page":"29","article-title":"Microscopic assessment of angiogenesis in tumors","volume":"46","author":"Fox","year":"2001","journal-title":"Methods Mol Med."},{"issue":"1","key":"10.1016\/j.lungcan.2020.09.022_bib0165","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF00666186","article-title":"Tumor angiogenesis in node-negative breast carcinomas--relationship with epidermal growth factor receptor, estrogen receptor, and survival","volume":"29","author":"Fox","year":"1994","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"10.1016\/j.lungcan.2020.09.022_bib0170","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1711770310","article-title":"Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis","volume":"177","author":"Fox","year":"1995","journal-title":"J Pathol."},{"issue":"6","key":"10.1016\/j.lungcan.2020.09.022_bib0175","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1054\/bjoc.2001.1997","article-title":"Angiogenesis is an independent prognostic factor in malignant mesothelioma","volume":"85","author":"Edwards","year":"2001","journal-title":"Br J Cancer."},{"issue":"1","key":"10.1016\/j.lungcan.2020.09.022_bib0180","first-page":"139","article-title":"The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients","volume":"6","author":"Hansen","year":"2000","journal-title":"Clin Cancer Res."},{"issue":"7-8","key":"10.1016\/j.lungcan.2020.09.022_bib0185","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/028418602321028337","article-title":"Chalkley Estimates of Angiogenesis in Early Breast Cancer - Relevance to Prognosis","volume":"41","author":"Offersen","year":"2002","journal-title":"Acta Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2020.09.022_bib0190","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.pathol.2016.07.009","article-title":"Vasculogenic mimicry in malignant mesothelioma: an experimental and immunohistochemical analysis","volume":"48","author":"Pulford","year":"2016","journal-title":"Pathology."},{"issue":"6","key":"10.1016\/j.lungcan.2020.09.022_bib0195","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ctrv.2012.12.005","article-title":"Malignant mesothelioma: new insights into a rare disease","volume":"39","author":"Remon","year":"2013","journal-title":"Cancer treatment reviews"},{"issue":"2","key":"10.1016\/j.lungcan.2020.09.022_bib0200","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D","article-title":"Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma","volume":"182","author":"Kumar-Singh","year":"1997","journal-title":"J Pathol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.09.022_bib0205","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J Thorac Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.09.022_bib0210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/JTO.0b013e31823085f4","article-title":"Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab","volume":"7","author":"Zhao","year":"2012","journal-title":"J Thorac Oncol."},{"issue":"6C","key":"10.1016\/j.lungcan.2020.09.022_bib0215","first-page":"4833","article-title":"Expression of vascular endothelial growth factor in malignant mesothelioma","volume":"26","author":"Aoe","year":"2006","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2020.09.022_bib0220","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J Pathol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.09.022_bib0225","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-018-4664-7","article-title":"The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence","volume":"169","author":"Jansson","year":"2018","journal-title":"Breast Cancer Res Treat."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:42:42Z","timestamp":1759236162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220306322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":45,"alternative-id":["S0169500220306322"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.09.022","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}